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PURPOSE. Cancer stem cells (CSCs) are a subpopulation of cells with the capacity to drive
tumor growth. While there is evidence of the existence of CSCs in uveal melanoma (UM),
there is no consensus on their defining markers. In this study, we examined putative CSC
markers in UM cell lines, primary UM (PUM), and normal choroidal melanocytes (NCM).
METHODS. Nonadherent sphere assays were used to assess the tumorigenic potential of 15
PUMs, 8 high (M3) and 7 low (D3) metastatic risk. Flow cytometry was used to compare the
expression of CSC markers between 10 PUMs and 4 NCMs, as well as in 8 UM cell lines grown
under adherent and nonadherent conditions. Based on the data generated and from TCGA
analyses, CD166 was investigated in detail, including its effect on cell migration using a tumor
transendothelial migration assay.
RESULTS. M3 PUM had a greater melanosphere-forming efficiency than D3 PUM. CD166 and
Nestin expression was upregulated in PUM compared to NCM by flow cytometry. UM cell
lines resistant to anoikis had increased levels of CD271, Nestin, and CD166 compared with
adherent cells. TCGA analysis showed that patients with higher CD166 expression had a
poorer prognosis: this was supported by a Mel270 CD166high subpopulation that had
enhanced migratory capabilities compared with CD166low cells. IHC showed that CD166 is
expressed in the cytoplasm and cell membrane of PUM cells.
CONCLUSIONS. UM contain a population of cells with characteristics of CSCs. In particular,
CD166high UM cells appear to represent a subpopulation with enhanced migratory capacity.
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Cancer stem cells (CSCs) are a subpopulation within a tumorwith the capacity to self-renew, generate the bulk of the
tumor and facilitate continued tumor propagation.1 It is also
believed that CSCs contribute to chemo- and radio-resistance in
tumors that relapse, despite ‘‘successful’’ first-line treatment.2
The enhanced survival mechanism(s) of CSCs enables them to
survive in the circulation and form distant metastases.3 Several
cell surface markers have been described in breast, colon, and
prostate carcinomas as well as other cancers, which putatively
identify/enrich for the CSCs.
In skin melanoma, CSC markers include CD271,4 CD133,5
CD166,6 Nestin,7 ABCB5,8 and CD20,9 which identify cells
able to form tumors when xenotransplanted in mice, to form
melanospheres (MS) in nonadherent culture, and showed a
stepwise increase in expression from nevi to metastatic
lesions.
Although only a few studies exist in UM, there is some
evidence for the existence of stem-like cells in UM cell
lines,10,11 and an association of high metastatic risk UM with
a primitive neuroectodermal phenotype.12 Putative CSC
markers identified in eight UM cell lines included Nestin,
CXCR4, CD44, and c-kit. In formalin-fixed paraffin embedded
(FFPE) UM, CD133, Pax6, Musashi, Nestin, Sox2, and ABCB5
were observed predominantly at the ‘‘invading’’ tumor edge.11
Doherty et al.13 demonstrated expression of ALDH, CD44, and
CD133 in UM cell lines and short-term cultures, although the
cellular phenotype altered in response to environmental
stimuli. They suggested this cellular plasticity may be related
to the neural crest origin of intraocular melanocytes and all UM
cells have the potential to drive tumor progression.
It is clear, therefore, there is lack a consensus regarding the
presence of CSCs in UM and the markers that can be used to
identify this subpopulation. In this study, we examined several
properties associated with CSCs in UM cell lines and short-term
cultures of primary UM (PUM) cells and normal choroidal
melanocytes (NCM). These include, expression of melanocytic,
neural crest and putative stem cell markers and resistance to
anoikis.
MATERIALS AND METHODS
Sample Collection
All PUM samples were obtained from the Ocular Oncology
Biobank (REC ref. no. 16/NW/0380) and were used with
patient consent and according to project-specific ethical
approvals from the Health Research Authority (REC ref. no.
11/NW/0759 and 15/SS/0097). Human umbilical vein endothe-
lial cells (HUVECs) were provided by Lugang Yu of the
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University of Liverpool. The study was conducted in accor-
dance with the tenets of the Declaration of Helsinki.
Four postmortem globes were obtained at the Centre for
Eye Research, University of Oslo, Norway and used for cornea
isolation and transplantation according to the ethically
approved protocol of the Cornea Bank (REK ref. no. 2017/
418). After isolation of the cornea, NCM were isolated and
cultured according to a standard protocol.
Cell Culture
Isolation and culturing of NCM was performed as previously
described.14 Briefly, the enucleated eye was washed with PBSþ
1% penicillin-streptomycin solution (Sigma Aldrich Corp.,
Dorset, UK). A circumferential incision was made in the sclera
and the vitreous, sensory neuroretina, and retinal pigment
epithelial cells were removed. The choroid was washed with
the PBS-antibiotic mix and peeled from the sclera. It was
mechanically minced with a blade and resuspended in a
solution of 0.2 U Dispase (Sigma Aldrich Corp.). Following
overnight incubation at 378C, the digested choroid was
collected, filtered, and spun down. The pelleted cells were
plated into a six-well plate in melanocyte growth medium
(Promocell, Heidelberg, Germany).
Culture of PUM cells was also performed as previously
published.15 The fresh tumor tissue was minced using a sterile
blade. The tissues pieces were then resuspended in collage-
nase IV (Sigma Aldrich Corp.) and incubated at 378C for 1 hour.
Isolated cells were counted and used either directly in the
nonadherent sphere assay or grown as adherent cultures until
they reached ~60% confluence. In both assays, PUM cells were
grown in 1:1 aMEM (Sigma): amnioselect (Metachem Diagnos-
tics Ltd, Northampton, UK), 10% fetal calf serum (FCS)
(Labtech International Ltd, Heathfield, UK), 2 mM L-glutamine
(Sigma) and antibiotics.
UM cell lines, derived from both primary (92.1,16
Mel270,17 MP41,18 MP4618) and metastatic UM (MUM)
(OMM1,19 MM66,18 OMM2.3,17 OMM2.517), were maintained
in RPMI medium (Life Technologies, Warrington, UK) with
10% FCS, 2 mM L-glutamine and antibiotics. Cells were
passaged once a week and used when they reached ~60%
confluence. Cell line details are included in Supplementary
Table S1. All cell lines were mycoplasma free at the time of
study and authenticated by STR profiling according to the
guidelines recommended by the International Cell Line
Authentication Committee (ICLAC).
HUVECs were cultured in a specialized medium, EGM (Lonza
Ltd, Slough, UK), which contains growth factors, supplements,
and antibiotics. The medium was changed every 3 days, and
cells were used when they formed a confluent monolayer.
Chromosomal Copy Number Analysis
The multiplex ligation dependent probe amplification (MLPA)
procedure for the assessment of chromosome 1, 3, 6, and 8
copy number alterations were performed as previously
described.20
Nonadherent Sphere Assay
PUM cells were seeded in 20 mL PUM medium, at a density of
2000 cells/mL into a 75-cm2 flask coated with poly 2-
hydroxyethyl methacrylate (poly-HEMA; Sigma Aldrich Corp.)
to prevent cell attachment. Every 7 days, 10 mL of medium was
replaced with fresh PUM medium (10 mL). After 21 days, MS of
at least 50 lm in diameter (size was determined using an
eyepiece graticule with crossed scales) were counted.
Flow Cytometry
The NCM, PUM and cell lines were used for flow cytometry
upon reaching ~60% confluence. Cell detachment was by
collagenase IV and nonenzymatic dissociation solution (Life
Technologies). After incubation for 5 minutes at 378C, the
blocking buffer (10%FCS, 0.02%EDTA in PBS) was added.
Centrifugation was performed at 250g for 2 minutes and
following cell counting, 200,000 cells were resuspended in 100
ll ‘‘flow cytometry’’ buffer (PBS containing 1% bovine serum
albumin: BSA). A fluorescently-labeled antibody was added to
the appropriate tubes for direct labeling of the surface
antigens. The antibodies used were all from Biolegend
(London, UK): PE-conjugated anti-CD166 (12.5 lg/ml), FITC-
conjugated anti-CD146 (10 lg/ml) and PE-conjugated anti-
CD133 (5 lg/ml). After 30 minutes, the samples were washed
with PBS and centrifuged at 250g for 10 minutes. The pellet
was suspended in 500 ll of buffer and analyzed in the FACS
Canto II cytometer (BD Biosciences, Berkshire, UK).
Indirect labeling for the intracellular proteins was per-
formed following cell fixation in 1% paraformaldehyde for 10
minutes. After washing with PBS, the cells were permeabilized
with 0.5% Tween-20 solution for 10 minutes. Blocking was
performed using 10% normal goat serum in 1% BSAþPBS for 10
minutes. The cells were washed with PBS and incubated with
the primary antibody for 30 minutes. An AlexaFluor 488–
conjugated fluorescent secondary antibody was then added for
a further 30 minutes. After a final wash step, the sample was
resuspended in 500 ll of flow cytometry buffer and analyzed
on the cytometer. The mouse monoclonal antibodies labeled
indirectly were Melan-A (DAKO, 1 lg/mL), Nestin (Abcam, 10
lg/mL) and CD271 (Abcam, 5 lg/mL).
Assessment of Anoikis Resistance
To assess anoikis resistance, UM cell lines were grown in
adherent and nonadherent (using ultralow attachment [ULA]
plates) conditions. Briefly, cell lines at ~60% confluence were
detached with a nonenzymatic cell dissociation solution. After
centrifugation at 1500g for 2 minutes, the cells were counted
and 53 105 cells were added to either a 75 cm2 tissue culture
treated flask or a 75 cm2 ULA flask (Sigma Aldrich Corp.) in
RPMIþ10% FCS. Cells were maintained in these conditions for
72 hours, then labeled for flow cytometry according to the
standard protocol.
Immunohistochemistry (IHC)
IHC for CD166 (Abcam, 44 lg/mL) was performed on 4-lm
FFPE sections using commercial equipment (Leica Bond RXm
System; Leica Microsystems Ltd, Milton Keynes, UK) and a
detection kit (Bond Polymer Refine Red Detection Kit; Leica
Biosystems, Inc., Buffalo Grove, IL, USA). Slides were
counterstained with hematoxylin and mounted using DPX
mountant (Sigma Aldrich, Corp.). Normal pancreas served as
the positive control; negative control was omission of the
primary antibody. Slides were scanned using a slide scanner
(Aperio CS2; Leica Biosystems, Inc.) and analyzed with imaging
software (Aperio Image Scope version 11.2; Leica Biosystems,
Inc.).
Fluorescence Activated Cell Sorting (FACS)
The Mel270 UM cell line was used for FACS because it contains
two distinct subpopulations, CD166high and CD166low. After
dissociation, 7 3 106 cells were resuspended in FACS buffer
(PBS, 1% BSA, 10% serum). They were then labeled with the
PE-conjugated CD166 antibody according to the protocol
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described above. After 30 minutes, samples were washed and
resuspended in FACS buffer. Cell sorting was performed using
the FACS Aria III (BD Biosciences). Following sorting, cells
were collected in RPMI mediumþ10% FCS and plated into 25-
cm2 flasks.
Tumor Transendothelial Migration Assay
To mimic the metastatic process of extravasation, a trans-
endothelial migration assay was performed as previously
described.21 First, HUVECs were harvested and counted:
30,000 cells were plated onto each 0.8-lm transwell insert in
a 24-well plate and media changed daily for 3 days. When a
confluent monolayer had formed, Mel270 cells were added
onto the HUVEC cell layer at a density of 40,000 cells per well
in RPMI containing 1% serum. The bottom of the chamber
contained RPMI þ 10% FCS. The plate was incubated at 378C
for 48 hours, after which the cell-dissociation and calcein-AM
solution was added for 1 hour. Fluorescence was measured in a
plate reader at a wavelength of 485 (excitation) and 520 nm
(emission).
Statistical Analysis
Student’s t-test or Mann–Whitney test was used to examine
linear variables where data did or did not fit a normal
distribution, respectively. When the Mann-Whitney test was
used to compare the medians between two groups (PUM and
NCM), a Bonferroni correction was applied and a value of P 
0.008 was considered statistically significant. In all other cases
P  0.05 was considered statistically significant. The difference
in proportion for marker expression in the UM cell lines was
assessed by z-statistics. Survival analysis was performed using
the Kaplan–Meier test. All analyses were performed using
statistical software (SPSS version 24.0; SPSS Science, Chicago,
IL, USA).
RESULTS
Details of UM cell lines used in the study are given in
Supplementary Table S1. Cells isolated from 10 PUM were used
for flow cytometry and a further 15 PUM for MS assays. The
details of the PUMs are provided in Supplementary Table S2.
Demographics of the four human NCM donors and the cause of
death are included in Supplementary Table S3.
Monosomy 3 UM Have Higher Colony Forming
Efficiency Than Disomy 3 UM
The 15 UM samples used for MS assays were tested for
chromosomal alterations by MLPA and classified as either being
at a high or low risk of developing metastasis, according to
chromosome 3 status, as previously described.20 When tested
for their MS-forming efficiency (MSFE), all M3 UM were able to
form MS (median 0.05%, range: 0.02%–0.14%). In contrast, D3
UM were not able to form MS in 4/7 samples tested (median
0%, range 0%–0.07%; Fig. 1).
CD166 and Nestin Are Upregulated in PUMs
Compared to NCMs
Short-term cultures of both NCMs and PUMs investigated by
flow cytometry found stem cell markers CD166 and Nestin to
be elevated in PUMs compared to NCMs. CD166 expression
in the cultured PUM was 4-fold greater (mean 78%, median
78%, range: 54%–100%) than its expression in the NCM
(mean 19%, median 16%, range 4%–41%; Supplementary
Table S4). This difference was statistically significant (P ¼
0.0003; Mann-Whitney). The mean Nestin expression in PUM
(mean 33%, median 19%, range: 0.04%–99%) was 1.6-fold
higher when compared to the mean expression level in NCM
(mean 20%, median 17%, range: 5%–42%). However, in-
creased Nestin expression (P ¼ 0.12) together with the
expression of Melan A (P¼0.12), CD271 (P¼0.14) CD146 (P
¼ 0.12) and CD133 (P ¼ 0.01) were not statistically
significantly different between PUM and NCM, using a
Mann-Whitney test (Fig. 2).
There were five PUMs with features of high metastatic risk
(M3). When the expression of CSC markers was compared
between M3 and D3 UM, the M3 UM had elevated expression
of CD271 and Nestin when compared to D3 tumors; however,
none of the CSC markers examined reached statistical
significance (Mann-Whitney test; Supplementary Table S3).
FIGURE 1. MSFE of PUM grown at low density in non-adherent culture conditions. A bar graph showing a greater MSFE for M3 UM (green) as
compared with the D3 UM (red).
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CSC Markers Are Upregulated in UM Cells During
Anoikis Resistance
Eight UM cell lines were also examined for CSC markers by
flow cytometry under adherent and nonadherent culture
conditions. These were PUM derived (92.1, Mel 270, MP41,
MP46), and MUM derived (OMM1, Omm2.3, Omm2.5, MM66).
Melan-A was expressed in at least half of all the cells in both
adherent and nonadherent culture (median 73% vs. 72%). The
expression of CD271 was low (median 1%, range 0.03%–33%)
in all cell lines grown as adherent cultures but increased
expression (median 9%, range 0.04%–18%) was noted in the
cells resistant to anoikis. These changes were statistically
significant (P < 0.01, z-statistic) in MP46, OMM1, and MM66.
The median expression of Nestin was 26% (range: 3%–80%) in
the adherent cultures. This increased in the cells that survived
anoikis (median 64%, range: 20%–98%; Fig. 3). Upregulation of
Nestin expression was observed in 7/8 of the cell lines
examined. This difference was statistically significant (P <
0.01, z-statistic) in the 92.1, MP41, MP46, OMM2.3, and OMM
2.5 cell lines (Supplementary Table S5).
CD133 was expressed in <1% of UM cells in both adherent
(median 0.3%, range: 0.06%–0.6%) and nonadherent cultures
(median 0.4%, range: 0.2%–0.8%). CD146 was expressed in
>70% of the cells examined in both culture conditions. CD166
expression was variable in the cell lines examined both in
adherent (median 35%, range: 3%–88%) and nonadherent
culture (median 31%, range: 2%–95%; Fig. 3). Three MUM cell
lines and one PUM, however, upregulated their mean
expression of CD166 during anoikis resistance as compared
with cells in adherent culture; OMM1 (88%–95%), OMM2.3
(4%–7%), OMM2.5 (18%–26%), and MP41 (3%–18%). Analyses
by z-statistics showed that these changes were statistically
significant only for MP41 cells (P < 0.01; Supplementary Table
S5).
CD166, Nestin and CD271 Gene Expression in PUM
Analyzed by TCGA
Data regarding mRNA expression of Nestin, CD271, and
CD166 were downloaded from GDC The Cancer Genome
Atlas (TCGA) database, which contains genetic information and
clinical/survival data of 80 well characterized PUM patients
followed-up for at least 5 years.22 Data were analyzed in the
Xena Browser and the results compared with chromosome 3
copy number variations, BAP1 mutations, and patient outcome
(Fig. 4).
Median expression levels of the genes (white color) were
used as the cutoff points and upregulation was displayed in red
while downregulation was displayed in blue in the heat maps.
The median expression levels (unit log2[fpkm-uqþ1]) of the
genes were: BAP1 (19.5), ALCAM (14.2), Nestin (19.0) and
CD271/NGRF (13.2). UM with M3 and decreased BAP1 gene
expression compared to the median were associated with
upregulation of CD166/ALCAM expression. Expression of
Nestin and CD271/NGRF was more variable across the 80
samples.
Kaplan-Meier plots (Fig. 5) were created using the median
expression levels as the cutoff and differences were analyzed
by Log rank tests. Survival probability was calculated based on
event (death from metastatic UM) and time to event (time in
years) as parameters. Three patients were censored during this
analysis; one who died from pancreatic cancer and two from
unknown causes. UM expressing CD166/ALCAM above the
median were associated with a worse prognosis than those
with CD166/ALCAM expression below the median (P ¼ 0.03,
Log rank). Expression of Nestin (P ¼ 0.59) and CD271/NGRF
(P ¼ 0.91) above and below the median had no statistically
significant association with patient survival. Based on data from
both the flow cytometry analyses and gene expression data,
the functional role of CD166/ALCAM was investigated further.
CD166high Subpopulation Has Higher Tumor
Transendothelial Migration Potential Than
CD166low
The influence of CD166 to aid migration and metastasis was
investigated using a transendothelial assay and CD166high and
CD166low Mel270 cells isolated by FACS (Fig. 6A). These were
plated separately on HUVEC cells under chemoattractant/
serum gradient conditions. After 48 hours, cells with
CD166high expression migrated across the HUVEC monolayer
significantly more than those with CD166low expression (P ¼
0.02, Mann-Whitney; Figs. 6B).
CD166 Is Expressed in PUM Tissue by IHC Analysis
FFPE sections of nine enucleated PUM were examined for
CD166 protein expression by IHC. These were the same tumor
samples used flow cytometry analysis.
Normal pancreas (positive controls) expressed CD166 on
the membrane of cells in the islets of Langerhans (Fig. 7A). In
FIGURE 2. Expression of CSC markers in the NCM (n¼4) vs. PUM (n¼
10) cells. The bars represent the min-max percentage expression,
while the line is drawn at the median expression level of the markers.
Statistically significant difference is shown with a star (P ¼ 0.0003;
Mann-Whitney).
FIGURE 3. Expression of CSC markers across eight UM cell lines
cultured in adherent (plate) and nonadherent (ULA) conditions. The
bars represent the min-max percentage expression, while the line is
drawn at the median expression level of the markers. The experiment
was repeated three times (n¼ 3).
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FIGURE 4. Heat map showing association between CD166/ALCAM, Nestin and CD271/NGFR expression to BAP1 and Chromosome 3 loss. The
patient samples are arranged in rows under column (A), chromosome 3 status in column (B), BAP1 in column (C), CD166/ALCAM in column (D),
Nestin in column (E) and CD271/NGFR in column (F). Blue color shows downregulation, red shows upregulation and white shows median
expression of a gene on a log scale. Higher CD166/ALCAM expression was more abundant in M3 UM with BAP1 mutations while Nestin and CD271
expression was variable across the 80 PUM samples.
FIGURE 5. Kaplan-Meier survival plots showing that (Left) CD166/ALCAM expression is significantly associated with survival, (P¼ 0.03, Log rank).
The gene expression levels of Nestin (Middle) and CD271/NGRF (Right) showed no significant association with patient survival.
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the tumor sections, endothelial cells and tumor-associated
macrophages (TAM) consistently expressed CD166 (Fig. 7B,
Supplementary Fig. S1).
CD166 expression was seen in both the cytoplasm and the
membrane of PUM cells. However, this was clear in only 2/9
samples examined. These two samples were from a D3, and an
M3, PUM. The M3 tumor had few (<20%) CD166 expressing
PUM cells (cytoplasmic and membranous) scattered through-
out the sample. In the D3 sample, staining was only found in
the anterior portion of the tumor (Fig. 7C). In this region, 70%
of the cells stained positive for CD166 (Figs. 7D–F), while PUM
cells in the rest of the tumor were negative. It was difficult to
determine cytoplasmic or membranous staining in the heavily
pigmented or macrophage dense tumor sections (4/9). The
NCMs expressed CD166 on their cell membrane in 2/9 cases
examined.
DISCUSSION
In this study, we have shown that poor prognosis (M3) UM are
able to form more melanospheres from single cells than D3
UM, indirectly suggesting an increased presence of CSCs.
Moreover, flow cytometry demonstrated significantly increased
expression of CD166 in PUM compared with NCM, with a
trend toward elevated expression for Nestin and CD271. It is of
interest that none of the markers examined were significantly
increased in M3 as compared with D3 UM, although elevated
CD166 mRNA was associated with M3, decreased BAP1 mRNA
and reduced survival time, suggesting that CD166 has an
important role in the pathogenesis and progression of UM.
A higher overall expression of CD166 in PUM as compared
to NCM is consistent with studies of skin melanoma where
primary tumors expressed more CD166 than benign lesions by
IHC.6,23 Nestin expression was also higher in the PUM
compared to the NCM, consistent with our previous findings.24
Our data for CD146 support the findings of Lai et al.25 who
examined expression of CD146 in the uvea. They reported that
CD146 is expressed in the NCM, FFPE tumor sections and UM
cell lines. However, the high levels of expression of this marker
in both UM and NCM suggest that it lacks specificity as a CSC
marker.
Resistance to anoikis is a hallmark of tumorigenesis and
metastasis, as it enables cancer cells to survive and spread in
the blood or lymphatic system.26 The different causes of
anoikis resistance in cancer cells include genetic instability,
FIGURE 6. (A) Flow cytometry profile of Mel 270 cell line. The expression level of the markers (%) is shown on top of the histograms. Isotype
controls were used to gate for the negative populations. The cells positive for CD166 (40.1%) are shown. (B) Bar graph representing the number of
Mel270 tumor cells migrating across the HUVEC layer. Experiments were repeated twice and mean 6 SD is shown. A Mann-Whitney test shows that
extravasation was significantly (*P¼ 0.02) higher in CD166high compared to CD166low cells.
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epithelial-mesenchymal transition, and overexpression of stem-
ness markers.27 CSCs in several cancers including breast have
been shown to be resistant to anoikis, form spheres in
nonadherent culture and have enhanced tumor growth
capacity.28
UM cells surviving anoikis showed an increased expression
of several markers previously associated with neural crest
development and stem cells: CD271, Nestin, and CD166.
CD271 has been shown to mark the CSC population in skin
melanoma. These cells were able to form tumors in xenograft
models that resembled the parent tumor.4,29 In UM, CD271
was also expressed in the cells that formed vasculogenic
mimicry patterns, a poor prognostic feature likely to cause
metastasis.30 Increased Nestin expression in PUM is associated
with poor prognostic parameters including M3 and chromo-
some 8q gain.24 These results suggest that PUM cells surviving
anoikis may be enriched by the CSC population, as evidenced
by their increased expression of stemness markers.
CD166/ALCAM, a cell adhesion molecule has been reported
to mark mesenchymal stem cells,31 hematopoietic progenitor
cells,32 and CSCs in prostate33 and colon cancer,34 glioblasto-
ma,35 and skin melanoma.6 Studies in skin melanoma have
described its role in controlling the transition from local cell
proliferation to tissue invasion.36,37 This is consistent with
increased migration observed in the CD166high Mel270 cells as
compared to CD166low cells. A previous study has shown that
silencing CD166 by shRNA knockdown in a high-ALCAM
expressing UM cell line (MUM-2B), resulted in reduced motility
in gap-closure assays and a reduction in invasiveness as
measured by a transwell migration assay.38 This suggests
CD166 may play a role in UM tumor cell motility, migration,
and invasion. Indeed, analysis of TCGA data demonstrated that
increased CD166/ALCAM gene expression was significantly
associated with metastasis and a reduced overall survival.
In PUM sections, CD166/ALCAM expression was abundant
in the cytoplasm of TAMs. These results support studies which
showed that CD166/ALCAM is expressed in macrophages of
arthritic patients in response to cytokine release.39 Tumor
endothelial cells also expressed CD166/ALCAM, which has
been reported to be involved in early embryonic hematopoiesis
and vasculoangiogenesis.32 CD166 expression has been
documented in the retina, stromal cells, and melanocytes of
mice eyes, where it is proposed to play a role in the
development, structure, and function of these cells.40 Expres-
sion of CD166/ALCAM in melanoma cells analyzed by IHC was
not as abundant as demonstrated by flow cytometry. The
presence of CD166 macrophages and endothelial cells may
account for this. However, its location was similar to that in
skin melanoma, being positive both in the membrane and the
cytoplasm of the tumor cells.
In conclusion, we have shown that UM contains a
population of cells with characteristics of CSCs in vitro. In
particular, CD166high UM cells may represent a subpopulation
with enhanced migratory capacity. Our future plans include
using in vivo models to investigate if these findings can be
recapitulated in living organisms.
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